Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Cunningham, JW, Vaduganathan, M, Claggett, BL, John, JE, Desai, AS, Lewis, EF, Zile, MR, Carson, P, Jhund, PS, Kober, L, Pitt, B, Shah, SJ, Swedberg, K, Anand, IS, Yusuf, S, McMurray, JJV, Pfeffer, MA & Solomon, SD 2020, 'Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials', JACC. Heart failure, bind 8, nr. 8, s. 618-626. https://doi.org/10.1016/j.jchf.2020.02.007

APA

Cunningham, J. W., Vaduganathan, M., Claggett, B. L., John, J. E., Desai, A. S., Lewis, E. F., Zile, M. R., Carson, P., Jhund, P. S., Kober, L., Pitt, B., Shah, S. J., Swedberg, K., Anand, I. S., Yusuf, S., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020). Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. JACC. Heart failure, 8(8), 618-626. https://doi.org/10.1016/j.jchf.2020.02.007

CBE

Cunningham JW, Vaduganathan M, Claggett BL, John JE, Desai AS, Lewis EF, Zile MR, Carson P, Jhund PS, Kober L, Pitt B, Shah SJ, Swedberg K, Anand IS, Yusuf S, McMurray JJV, Pfeffer MA, Solomon SD. 2020. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. JACC. Heart failure. 8(8):618-626. https://doi.org/10.1016/j.jchf.2020.02.007

MLA

Vancouver

Author

Cunningham, Jonathan W ; Vaduganathan, Muthiah ; Claggett, Brian L ; John, Jenine E ; Desai, Akshay S ; Lewis, Eldrin F ; Zile, Michael R ; Carson, Peter ; Jhund, Pardeep S ; Kober, Lars ; Pitt, Bertram ; Shah, Sanjiv J ; Swedberg, Karl ; Anand, Inder S ; Yusuf, Salim ; McMurray, John J V ; Pfeffer, Marc A ; Solomon, Scott D. / Myocardial Infarction in Heart Failure With Preserved Ejection Fraction : Pooled Analysis of 3 Clinical Trials. I: JACC. Heart failure. 2020 ; Bind 8, Nr. 8. s. 618-626.

Bibtex

@article{2ca092fdb9bc45b8973175e3ac696108,
title = "Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials",
abstract = "OBJECTIVES: The authors investigated the relationship between past or incident myocardial infarction (MI) and cardiovascular (CV) events in heart failure with preserved ejection fraction (HFpEF).BACKGROUND: MI and HFpEF share some common risk factors. The prognostic significance of MI in patients with HFpEF is uncertain.METHODS: The authors pooled data from 3 trials-CHARM Preserved (Candesartan Cilexietil in Heart Failure Assessment of Reduction in Mortality and Morbidity), I-Preserve (Irbesartan in Heart Failure With Preserved Systolic Function), and the Americas region of TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) (N = 8,916)-and examined whether MI before or following enrollment independently predicted CV death and heart failure (HF) hospitalization.RESULTS: At baseline, 2,668 patients (30%) had history of MI. Prior MI was independently associated with greater risk of CV death (4.7 vs. 3.5 events/100 patient-years [py], adjusted hazard ratio [HR]: 1.42 [95% confidence interval (CI): 1.23 to 1.64]; p < 0.001). Excess sudden death drove this difference (1.9 vs. 1.2 events/100 py, adjusted HR: 1.55 [95% CI: 1.23 to 1.97]; p < 0.001). There was no difference in HF hospitalization (5.9 vs. 5.5 events/100 py, adjusted HR: 1.05, 95% CI: 0.92 to 1.19) or HF death by prior MI. During follow-up, MI occurred in 336 patients (3.8%). Risk of CV death increased 31-fold in the first 30 days after first post-enrollment MI, and remained 58% higher beyond 1 year after MI. Risk of first or recurrent HF hospitalization increased 2.4-fold after MI.CONCLUSIONS: Prior MI in HFpEF is associated with greater CV and sudden death but similar risk of HF outcomes. Patients with HFpEF who experience MI are at high risk of subsequent CV death and HF hospitalization. These data highlight the importance of primary and secondary prevention of MI in patients with HFpEF. (Candesartan Cilexietil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM Preserved]; NCT00634712; Irbesartan in Heart Failure With Preserved Systolic Function [I-Preserve]; NCT00095238; and Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist [TOPCAT]; NCT00094302).",
author = "Cunningham, {Jonathan W} and Muthiah Vaduganathan and Claggett, {Brian L} and John, {Jenine E} and Desai, {Akshay S} and Lewis, {Eldrin F} and Zile, {Michael R} and Peter Carson and Jhund, {Pardeep S} and Lars Kober and Bertram Pitt and Shah, {Sanjiv J} and Karl Swedberg and Anand, {Inder S} and Salim Yusuf and McMurray, {John J V} and Pfeffer, {Marc A} and Solomon, {Scott D}",
note = "Copyright {\textcopyright} 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.",
year = "2020",
month = aug,
doi = "10.1016/j.jchf.2020.02.007",
language = "English",
volume = "8",
pages = "618--626",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier BV",
number = "8",

}

RIS

TY - JOUR

T1 - Myocardial Infarction in Heart Failure With Preserved Ejection Fraction

T2 - Pooled Analysis of 3 Clinical Trials

AU - Cunningham, Jonathan W

AU - Vaduganathan, Muthiah

AU - Claggett, Brian L

AU - John, Jenine E

AU - Desai, Akshay S

AU - Lewis, Eldrin F

AU - Zile, Michael R

AU - Carson, Peter

AU - Jhund, Pardeep S

AU - Kober, Lars

AU - Pitt, Bertram

AU - Shah, Sanjiv J

AU - Swedberg, Karl

AU - Anand, Inder S

AU - Yusuf, Salim

AU - McMurray, John J V

AU - Pfeffer, Marc A

AU - Solomon, Scott D

N1 - Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PY - 2020/8

Y1 - 2020/8

N2 - OBJECTIVES: The authors investigated the relationship between past or incident myocardial infarction (MI) and cardiovascular (CV) events in heart failure with preserved ejection fraction (HFpEF).BACKGROUND: MI and HFpEF share some common risk factors. The prognostic significance of MI in patients with HFpEF is uncertain.METHODS: The authors pooled data from 3 trials-CHARM Preserved (Candesartan Cilexietil in Heart Failure Assessment of Reduction in Mortality and Morbidity), I-Preserve (Irbesartan in Heart Failure With Preserved Systolic Function), and the Americas region of TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) (N = 8,916)-and examined whether MI before or following enrollment independently predicted CV death and heart failure (HF) hospitalization.RESULTS: At baseline, 2,668 patients (30%) had history of MI. Prior MI was independently associated with greater risk of CV death (4.7 vs. 3.5 events/100 patient-years [py], adjusted hazard ratio [HR]: 1.42 [95% confidence interval (CI): 1.23 to 1.64]; p < 0.001). Excess sudden death drove this difference (1.9 vs. 1.2 events/100 py, adjusted HR: 1.55 [95% CI: 1.23 to 1.97]; p < 0.001). There was no difference in HF hospitalization (5.9 vs. 5.5 events/100 py, adjusted HR: 1.05, 95% CI: 0.92 to 1.19) or HF death by prior MI. During follow-up, MI occurred in 336 patients (3.8%). Risk of CV death increased 31-fold in the first 30 days after first post-enrollment MI, and remained 58% higher beyond 1 year after MI. Risk of first or recurrent HF hospitalization increased 2.4-fold after MI.CONCLUSIONS: Prior MI in HFpEF is associated with greater CV and sudden death but similar risk of HF outcomes. Patients with HFpEF who experience MI are at high risk of subsequent CV death and HF hospitalization. These data highlight the importance of primary and secondary prevention of MI in patients with HFpEF. (Candesartan Cilexietil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM Preserved]; NCT00634712; Irbesartan in Heart Failure With Preserved Systolic Function [I-Preserve]; NCT00095238; and Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist [TOPCAT]; NCT00094302).

AB - OBJECTIVES: The authors investigated the relationship between past or incident myocardial infarction (MI) and cardiovascular (CV) events in heart failure with preserved ejection fraction (HFpEF).BACKGROUND: MI and HFpEF share some common risk factors. The prognostic significance of MI in patients with HFpEF is uncertain.METHODS: The authors pooled data from 3 trials-CHARM Preserved (Candesartan Cilexietil in Heart Failure Assessment of Reduction in Mortality and Morbidity), I-Preserve (Irbesartan in Heart Failure With Preserved Systolic Function), and the Americas region of TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) (N = 8,916)-and examined whether MI before or following enrollment independently predicted CV death and heart failure (HF) hospitalization.RESULTS: At baseline, 2,668 patients (30%) had history of MI. Prior MI was independently associated with greater risk of CV death (4.7 vs. 3.5 events/100 patient-years [py], adjusted hazard ratio [HR]: 1.42 [95% confidence interval (CI): 1.23 to 1.64]; p < 0.001). Excess sudden death drove this difference (1.9 vs. 1.2 events/100 py, adjusted HR: 1.55 [95% CI: 1.23 to 1.97]; p < 0.001). There was no difference in HF hospitalization (5.9 vs. 5.5 events/100 py, adjusted HR: 1.05, 95% CI: 0.92 to 1.19) or HF death by prior MI. During follow-up, MI occurred in 336 patients (3.8%). Risk of CV death increased 31-fold in the first 30 days after first post-enrollment MI, and remained 58% higher beyond 1 year after MI. Risk of first or recurrent HF hospitalization increased 2.4-fold after MI.CONCLUSIONS: Prior MI in HFpEF is associated with greater CV and sudden death but similar risk of HF outcomes. Patients with HFpEF who experience MI are at high risk of subsequent CV death and HF hospitalization. These data highlight the importance of primary and secondary prevention of MI in patients with HFpEF. (Candesartan Cilexietil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM Preserved]; NCT00634712; Irbesartan in Heart Failure With Preserved Systolic Function [I-Preserve]; NCT00095238; and Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist [TOPCAT]; NCT00094302).

U2 - 10.1016/j.jchf.2020.02.007

DO - 10.1016/j.jchf.2020.02.007

M3 - Journal article

C2 - 32387067

VL - 8

SP - 618

EP - 626

JO - JACC: Heart Failure

JF - JACC: Heart Failure

SN - 2213-1779

IS - 8

ER -

ID: 62248458